참고문헌
- Adachi S, Yoshimura T, Matsuoka T, et al (2011). [Appearance of skin and nail toxicity in patients with breast cancer who underwent trastuzumab-containing chemotherapy]. Gan To Kagaku Ryoho, 38, 1453-6.
- Afsharfard A, Mozaffar M, Orang E, et al (2013). Trends in epidemiology, clinical and histopathological characteristics of breast cancer in Iran: results of a 17 year study. Asian Pac J Cancer Prev, 14, 6905-11. https://doi.org/10.7314/APJCP.2013.14.11.6905
- Ahmad S, Gupta S, Kumar R, et al (2014). Herceptin resistance database for understanding mechanism of resistance in breast cancer patients. Sci Rep, 4, 4483.
- Albanell J, Baselga J (1999). Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc), 35, 931-46.
- Albanell J, Codony J, Rovira A, et al (2003). Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol, 532, 253-68. https://doi.org/10.1007/978-1-4615-0081-0_21
- Alshenawy HA (2012). Prevalence of androgen receptors in invasive breast carcinoma and its relation with estrogen receptor, progesterone receptor and Her2/neu expression. J Egypt Natl Canc Inst, 24, 77-83. https://doi.org/10.1016/j.jnci.2012.04.001
- Althuis MD, Dozier JM, Anderson WF, et al (2005). Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol, 34, 405-12. https://doi.org/10.1093/ije/dyh414
- Avila AD, Calderon CF, Perez RM, et al (2007). Construction of an immunotoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin. Biol Res, 40, 173-83.
- Bandala C, Perez-Santos JL, Lara-Padilla E, et al (2013). Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line. Asian Pac J Cancer Prev, 14, 891-4. https://doi.org/10.7314/APJCP.2013.14.2.891
- Barok M, Tanner M, Koninki K, et al (2011). Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett, 306, 171-9. https://doi.org/10.1016/j.canlet.2011.03.002
- Beuzeboc P, Scholl S, Garau XS, et al (1999). [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?]. Bull Cancer, 86, 544-9.
- Chan YL, Correll CC, Wool IG (2004). The location and the significance of a cross-link between the sarcin/ricin domain of ribosomal RNA and the elongation factor-G. J Mol Biol, 337, 263-72. https://doi.org/10.1016/j.jmb.2004.01.020
- Corradino B, Di Lorenzo S, Moschella F (2012). Botulinum toxin A for oral cavity cancer patients: in microsurgical patients BTX injections in major salivary glands temporarily reduce salivary production and the risk of local complications related to saliva stagnation. Toxins (Basel), 4, 956-61. https://doi.org/10.3390/toxins4110956
- d'Agnano I, Bucci B, Mottolese M, et al (1996). DNA ploidy, cell kinetics, and epidermal growth factor receptor and HER2/neu oncoprotein expression in primary operable breast cancer. Ann N Y Acad Sci, 784, 472-81. https://doi.org/10.1111/j.1749-6632.1996.tb16266.x
- Dang C, Lin N, Moy B, et al (2010). Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/ amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol, 28, 2982-8. https://doi.org/10.1200/JCO.2009.26.5900
- Dao KL, Sawant RR, Hendricks JA, et al (2012). Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen-doxorubicin bioconjugate for targeting estrogen receptor-positive breast cancer cells. Bioconjug Chem, 23, 785-95. https://doi.org/10.1021/bc200645n
- DeSantis C, Ma J, Bryan L, et al (2014). Breast cancer statistics, 2013. CA Cancer J Clin, 64, 52-62. https://doi.org/10.3322/caac.21203
- Hosseini MS, Arab M, Nemati Honar B, et al (2013). Age - specific incidence rate change at breast Cancer and its different histopathologic subtypes in Iran and Western countries. Pak J Med Sci, 29, 1354-7.
- Houchins JP (2000). Immunotoxin-induced apoptosis. Stem Cells, 18, 384-5. https://doi.org/10.1634/stemcells.18-5-384
- Kaufmann R, Muller P, Hildenbrand G, et al (2011). Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using localization microscopy. J Microsc, 242, 46-54. https://doi.org/10.1111/j.1365-2818.2010.03436.x
- Lattova E, Tomanek B, Bartusik D, et al (2010). N-glycomic changes in human breast carcinoma MCF-7 and T-lymphoblastoid cells after treatment with herceptin and herceptin/Lipoplex. J Proteome Res, 9, 1533-40. https://doi.org/10.1021/pr9010266
- Layeeque R, Hochberg J, Siegel E, et al (2004). Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann Surg, 240, 608-13.
- Li LX, Tang YM, Zhang HZ, et al (2008). [Preparation of the immunotoxin 2E8-norcantharidin and its targeting killing effect in vitro]. Zhonghua Er Ke Za Zhi, 46, 493-7.
- Meyer S, Leusen JH, Boross P (2014). Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs, 6.
- Mohanraj D, Ramakrishnan S (1995). Cytotoxic effects of ricin without an interchain disulfide bond: genetic modification and chemical crosslinking studies. Biochim Biophys Acta, 1243, 399-406. https://doi.org/10.1016/0304-4165(94)00166-U
- Naumann MK, Hamm H, Lowe NJ (2002). Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol, 147, 1218-26. https://doi.org/10.1046/j.1365-2133.2002.05059.x
- Nezu A, Iwasaki N (2013). [Botulinum toxin in the treatment of cerebral palsy in childhood: the domesteic expert opinions and the role of pediatric neurologists in the management for severely handicapped children]. No To Hattatsu, 45, 147-9.
- Olver IN (2008). Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when. Future Oncol, 4, 125-31. https://doi.org/10.2217/14796694.4.1.125
- Perez EA (2001). The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies. Curr Oncol Rep, 3, 516-22. https://doi.org/10.1007/s11912-001-0073-9
- Ravindra P, Jackson BL, Parkinson RJ (2013). Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox((R)) ) or abobotulinumtoxinA (Dysport((R)) ) make a difference? BJU Int, 112, 94-9. https://doi.org/10.1111/bju.12028
- Ray P (1993). Botulinum toxin A inhibits acetylcholine release from cultured neurons in vitro. In Vitro Cell Dev Biol Anim, 29, 456-60. https://doi.org/10.1007/BF02639379
- Singh R, Samant U, Hyland S, et al (2007). Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)- ETA on breast carcinoma cells and primary breast tumors. Mol Cancer Ther, 6, 562-9. https://doi.org/10.1158/1535-7163.MCT-06-0604
- Sparano JA (2001). Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol, 28, 20-7. https://doi.org/10.1053/sonc.2001.22813
- Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70. https://doi.org/10.7314/APJCP.2012.13.1.367
- Tsai HT, Isaacs C, Fu AZ, et al (2014). Risk of cardiovascular adverse events from trastuzumab (Herceptin((R))) in elderly persons with breast cancer: a population-based study. Breast Cancer Res Treat, 144, 163-70. https://doi.org/10.1007/s10549-014-2836-7
- Untch M, Ditsch N, Hermelink K (2003). Immunotherapy: new options in breast cancer treatment. Expert Rev Anticancer Ther, 3, 403-8. https://doi.org/10.1586/14737140.3.3.403
- Wei X, Juan ZX, Min FX, et al (2011). Recombinant immunotoxin anti-c-Met/PE38KDEL inhibits proliferation and promotes apoptosis of gastric cancer cells. J Exp Clin Cancer Res, 30, 67. https://doi.org/10.1186/1756-9966-30-67
- Yoneyama T, Miyata K, Chikai T, et al (2008). Clostridium botulinum serotype D neurotoxin and toxin complex bind to bovine aortic endothelial cells via sialic acid. FEMS Immunol Med Microbiol, 54, 290-8. https://doi.org/10.1111/j.1574-695X.2008.00475.x
피인용 문헌
- Simultaneous targeted inhibition of Sox2-Oct4 transcription factors using decoy oligodeoxynucleotides to repress stemness properties in mouse embryonic stem cells vol.41, pp.12, 2017, https://doi.org/10.1002/cbin.10847